The Pivotal Scientific Limited Antibody Market Report

Pivotal Scientific

Mar 26, 2020

Science 1

The Threat of Pandemic to Antibody Supply Chain Stability¹

By June this year you will have access to purchase, or will have received, as a PSL Alliance member, the Pivotal Scientific Antibody Market Report. We have decided this year, after releasing the 2020 report to step back and reassess for 2-3 years and let the market develop before producing another insightful report.

Many companies use this report as a tool to plan their Sales and Marketing activity because the information in the report enables them to adapt and change their business according to the current market situation. A bonus this year is that this year our good friends at Rockland Immunochemicals, Inc. have written a very insightful industry article titled: The Threat of Pandemic to Antibody Supply Chain Stability

This article is a great addition to the Antibody Market Report and will be well worth a full read. It covers the following topics:

  • Epidemiology of 2019-nCoV and COVID-19
  • Supply Chain Disruptions
  • Risk Mitigation and Remediation of Shortages of
    Life Science Reagents

Not only is the report highlighting trends within our industry but is now looking at the bigger global picture and giving companies an insight into future contingency planning should we ever, god forbid, experience another pandemic such as this in the future. It gives insight into how companies can reduce the risk should situations like this happen again.

The article looks from a business continuity perspective at supply chain stability within Life Science which may be in Jeopardy, but the article goes on to advise about the strategies that can be put in place to remediate much of this risk. It looks at different supply chains and how stability differs depending on the reagent types (RUO, IVD, Pre-Clinical & Therapeutics).

As a scientific community we must work together to resolve Covid-19 and all other life-threatening diseases. Providing insightful information from members of our Alliance community, such as this, and other technologies and information, may, eventually get some of the answers we need

Carl A. Ascoli1*  

1 Rockland Immunochemicals Inc., Limerick, PA, USA.